In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Bittorf, Founder and Principal Consultant of SCxCMC. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering: Joining a little company called Vertex Pharma when it was looking to be innovative The leap of faith required to become a consultant, and why helping smaller businesses makes a bigger difference An insight into the sentiment of virtual, small, and emerging biotechs after a brutal 12 months What the most significant factor is in CDMO selection for biotechs, as well as other critical components Why CMC is a crucial investment from pre-IND to phase 2 to get things done on time Kevin is an experienced consultant who has demonstrated success in pharmaceutical development (innovator and generics) and technical innovation. Leveraging his extensive experience in GMP, business development, contract manufacturing, and long-term strategy, Kevin partners with biopharma CEOs and executives to guide their companies through groundbreaking pharmaceutical advancements by evaluating strategy, attaining government approvals, and developing new and emerging technologies that improve the development lifecycle. He has formed multiple non-profit conferences, including the Advancing Drug Development Forum, which examines how innovations are brought from inception to regulatory approval. He has spent time at Vertex and Trek Therapeutics and advising several CDMOs. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.